2. Protein Tyrosine Kinase/RTK
  3. VEGFR
  4. Parsatuzumab

Parsatuzumab  (Synonyms: Anti-EGFL7; RG 7414)

Cat. No.: HY-P99215 Pureza: 97.40%
COA
SDS
Technical Support

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition.

Para uso exclusivo en investigación. No vendemos a pacientes.

No. CAS : 1312797-14-0

Tamaño Precio Stock Cantidad
1 mg En stock
5 mg En stock
10 mg En stock
50 mg   Obtener un presupuesto  
100 mg   Obtener un presupuesto  

* Seleccione Cantidad antes de agregar artículos.

This product is a controlled substance and not for sale in your territory.

Parsatuzumab Related Antibodies

Top Publications Citing Use of Products

Ver todos los productos específicos de isoformas VEGFR:

Ver todas las isoformas
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

  • Actividad biológica

  • Pureza y Documentación

  • Referencias

  • Revisión del cliente

Descripciòn

Parsatuzumab (Anti-EGFL7; RG 7414) is a humanized monoclonal antibody, acts as an immunomodulator and binds to EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition[1].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

EGFL7
In Vitro

EGFL7 is a vascular-restricted extracellular matrix protein that promotes endothelial cell adhesion and survival[1].
Parsatuzumab (48 h) inhibits cell proliferation and increases apoptosis against patient-derived xenograft (PDX) cells[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Parsatuzumab Related Antibodies

Cell Viability Assay[2]

Cell Line: Patient-derived xenograft (PDX) cells
Concentration: /
Incubation Time: 48 hours
Result: Inhibited cell proliferation by 70% from 20%, and resulted in apoptosis increases by 67-87% from 8-17%.
In Vivo

Parsatuzumab (anti-EGFL7) enhances the antiangiogenesis, tumor growth control, and survival associated with antiVEGF monotherapy in several xenograft and genetically engineered murine tumor models[1].
Parsatuzumab (50 mg/kg; i.v.; 3 times per week) targets EGFL7 and inhibits mantle cell lymphoma (MCL) cell growth and prolongs survival in mouse models of MCL[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: NSG mice injected with Rec1 cells (s.c.)[2]
Dosage: 50 mg/kg
Administration: Intravenous injection; 3 times per week; sacrificed mice when tumor reached end point criteria
Result: Significantly decreased tumor volume than IgG and increased survival of mice.
Gene ID

51162  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Peso molecular

148.22 kDa

No. CAS
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Parsatuzumab]
Envío

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Almacenamiento

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG1 kappa
Biological Activity
  • Immobilized EGFL7/VE-Statin Protein, Human can bind Parsatuzumab. The EC50 for this effect is 12.19 ng/mL.
Pureza y Documentación

Purity: 97.94%

SDS (251 KB)

COA (232 KB) SDS-PAGE (79 KB) SEC-HPLC (143 KB)

Inhibitory Antibodies User Guide (603 KB)
Referencias
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Parsatuzumab Related Classifications

  • Calculadora de molaridad

  • Calculadora de dilución

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Parsatuzumab1312797-14-0Anti-EGFL7 RG 7414RG7414RG 7414RG-7414VEGFRVascular endothelial growth factor receptormetastatic colorectal cancernonsquamous non-small cell lung cancermantle cell lymphomapatient-derived xenograft cellsPDXvascular endothelial growth factorVEGFInhibitorinhibitorinhibit

Productos vistos recientemente:

Consulta en línea

Your information is safe with us. * Required Fields.

Nombre del producto

  

Requested Quantity *

Nombre del solicitante *

 

Saludo

Direcciòn del E-mail *

 

Número de teléfono *

Department

 

Nombre de la Organizaciòn *

City

Provincia

Country or Region *

      

Observaciones

Consulta para venta a granel

Inquiry Information

Nombre del producto:
Parsatuzumab
Cat. No.:
HY-P99215
Cantidad:
MCE Japan Authorized Agent:

Revisión del cliente

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nombre del producto

  

Lot #

Nombre del solicitante *

 

Direcciòn del E-mail *

Número de teléfono

 

Department *

Nombre de la Organizaciòn *

 

Country or Region *

Observaciones

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.